Higher sales and gross margin in Q3 EBIT revised up 12.
Q3 in line with promising outlook for 2025 Large revisions as Kaktus divestment moving from '24e to ...
Trots att försäljning och resultat kom in under våra förväntningar i kvartalet kvarstår vår positiva...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 16% for the quarter...
Redeye shares its initial take on Physitrack’s Q3 results, which were generally in line with our mod...
Redeye gives a short comment on yesterday’s news that Curasight has announced brain cancer as the fi...
Redeye sees a solid Q3 report with an improved cash burn, and we welcome the increased gross margin ...
Redeye comments in EG7’s Q3-results which were better than expected, driven by strong profitability ...
Redeye provides an updated view on Nanologica following the company’s Q3 report.
In its CMD, Vaisala outlined its strategy and updated long-term financial targets.
Redeye reiterates its valuation following the Q3 2024 report, which showed slight positive deviation...
Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate acco...
Investors House reported Q3 2024 revenue of EUR 2.4m, 10% below our estimate, while net operating in...
Nettoomsättningen för det tredje kvartalet uppgick till 113,8 MSEK (97,5), vilket motsvarade en orga...
FX/Other hampered the results, underlying in line Crypto rallying, we raise adj.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denm...
Redeye comments on the new ALG.APV-527 phase I data.
Europe recovered and FY guidance kept EBITA cut 2-4%, eyes starting to shift to 2025e Higher organic...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to e...
